dopaminergic neurone
Recently Published Documents


TOTAL DOCUMENTS

8
(FIVE YEARS 0)

H-INDEX

4
(FIVE YEARS 0)

2003 ◽  
Vol 88 (3) ◽  
pp. 698-707 ◽  
Author(s):  
Jette Bisgaard Boll ◽  
Marie Aavang Geist ◽  
Gabriele S. Kaminski Schierle ◽  
Karina Petersen ◽  
Marcel Leist ◽  
...  
Keyword(s):  

BioEssays ◽  
1996 ◽  
Vol 18 (10) ◽  
pp. 817-824 ◽  
Author(s):  
Carla Perrone-Capano ◽  
Umberto di Porzio

1977 ◽  
Vol 15 (15) ◽  
pp. 57-59

The major tranquillisers (neuroleptics) have been in use for over 20 years to treat patients with schizophrenia. The main groups are the phenothiazines, the butyrophenones and the thioxanthenes, and all block dopaminergic neurone transmission. They are used to tranquillise disturbed patients with acute or acute-on-chronic episodes of schizophrenia, and as maintenance therapy for the suppression of psychotic phenomena in chronic patients. The general consensus is that they have improved the outlook for schizophrenic patients. Nevertheless, there are still many difficulties in their use. How can their prescription be approached rationally?


Sign in / Sign up

Export Citation Format

Share Document